An eco-friendly HPLC-UV method for the determination of risedronate in its bulk and tablet dosage form with application to content uniformity,dissolution and stability testing

Risedronate is a nitrogen-containing bisphosphonate for the treatment and prevention of postmenopausal osteoporosis. The current work aims to develop a novel green HPLC-UV method for the rapid analysis of risedronate sodium in bulk and tablet formulation. The analyzed samples were separated on Waters Atlantis dC18 (150 mm × 3.9 mm; 5 μm) column using a green mobile phase consisting of potassium phosphate buffer pH 2.9 and potassium edetate buffer pH 9.5 in a ratio of 1:2, the final pH was adjusted to 6.8 with phosphoric acid, the mobile phase was pumped at a rate of 1.0 mL/min, with column temperature set at 30 °C, eluted samples were detected at 263 nm and the chromatographic run time was 3.0 min. The method was found to be linear over the concentration range of 14–140 μg/mL with a correlation coefficient (r²) of 0.9994. Accuracy and precision were evaluated from three QC samples (LQC, MQC and HQC) together with the five calibrators where the percentage accuracy was found to be 101.84%. Processed quality control samples of risedronate sodium were tested for stability at different conditions, short term, long term and freeze- thaw stability. The current method was further extended to study the content uniformity of Actonel® tablets following United States Pharmacopoeia (USP) guidelines. The proposed method was fully validated as per ICH guidelines.     

Oral Dispersible System: A New Approach in Drug Delivery System

Dosage form is a mean used for the delivery of drug to a living body. In order to get the desired effect the drug should be delivered to its site of action at such rate and concentration to achieve the maximum therapeutic effect and minimum adverse effect. Since oral route is still widely accepted route but having a common drawback of difficulty in swallowing of tablets and capsules. Therefore a lot of research has been done on novel drug delivery systems. This review is about oral dispersible tablets a novel approach in drug delivery systems that are now a day''s more focused in formulation world, and laid a new path that, helped the patients to build their compliance level with the therapy, also reduced the cost and ease the administration especially in case of pediatrics and geriatrics. Quick absorption, rapid onset of action and reduction in drug loss properties are the basic advantages of this dosage form.     

胃痛宁片质量标准的研究

目的 建立胃痛宁片的质量标准.方法 采用TLC法对处方中龙胆粉进行定性鉴别,采用HPLC法测定蒲公英提取物中咖啡酸的质量分数.结果 在薄层色谱中可检出龙胆苦苷的特征斑点;咖啡酸回归方程为A=42.128 6ρ-19.133 2(r2=1),在6.29～ 62.9 μg/mL范围内线性关系良好,平均加样回收率为96.4％,RSD为0.28％(n=6).结论 所建立的定性方法专属性强,定量方法简便、准确,能有效地控制胃痛宁片的质量.     

V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori

Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on H. pylori infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of H. pylori infection in peptic ulcer disease were also reviewed.     

左氧氟沙星为基础的三联疗法根除幽门螺旋杆菌的疗效探讨

目的：探讨左氧氟沙星为基础的三联疗法根除幽门螺旋杆菌的临床治疗效果。方法方便选择2013年9月—2015年3月期间该院收治的120例Hp感染者作为实验对象，随机数字表法将患者分为对照组（n=60例）和观察组（n=60例），对照组采用标准三联法治疗，观察组采用以左氧氟沙星为基础的三联疗法治疗，观察两组患者Hp根除情况及恶心呕吐、腹部不适等不良反应发生情况。结果观察组Hp根除率显著高于对照组，差异有统计学意义（P<0.05），观察组总不良反应发生率为8.33%（5/60)，对照组总不良反应发生率为13.33%（8/60)，观察组不良反应发生率低于对照组，差异不具有统计学意义（P>0.05）。结论 Hp患者采用以左氧氟沙星为基础的三联疗法治疗，临床疗效较好，能够有效提高Hp根除率，并且不良反应发生率低，安全可靠，值得临床推广使用。     

注射用盐酸柔红霉素的质量评价

目的 按照国家计划抽验要求，评价国内不同企业生产的注射用盐酸柔红霉素的质量。方法 按国家标准检验与探索性研究相结合，对抽验样品进行检验，对检验结果进行统计分析。结果 共抽取样品17批次，按国家标准检验合格率100.0%。探索性研究对主要杂质的来源与结构进行了研究；建立溶液的澄清度检查方法；对包材相容性及稳定性进行了考察。结论 目前国内注射用盐酸柔红霉素总体质量较好；现行标准有待进一步提高，建议现行标准修订有关物质检查方法，增加特定杂质的控制，增加溶液的澄清度检查；建议企业优化生产工艺，以提高产品质量。     

甲状腺素钠联合硒酵母片对甲状腺功能减退症患者的有效性及对血管内皮功能的影响

目的探讨甲状腺素钠联合硒酵母片对甲状腺功能减退症患者的有效性及血管内皮功能的影响。方法选取2017年3月～2018年3月期间我院收治的甲状腺功能减退症的90例患者作为研究对象,根据治疗方式的不同分为研究组与对照组,各45例。对照组采用甲状腺素钠治疗,研究组患者采用甲状腺素钠联合硒酵母片治疗。比较两组患者甲状腺抗体的相关指标,血管内皮功能的相关指标以及出现的不良反应情况等。结果治疗前后两组患者甲状腺抗体的相关指标无显著差异(P0.05),治疗后研究组患者改善程度与对照组比较明显较好;研究组患者的AT-Ⅲ及HDL-C水平与对照组比较显著较高,而TC、CRP、LDL-C以及FIB水平与对照组相比显著降低(P0.05);研究组患者不良反应的总发生率与对照组相比明显降低(P0.05)。结论甲状腺功能减退症的患者采用甲状腺素钠与硒酵母片联合治疗,有助于促进患者甲状腺功能以及血管内皮功能的改善,同时不良反应的情况较少,安全可靠,对预后有积极的促进作用。     

复方盐酸阿替卡因在牙体牙髓病治疗中的应用效果分析

目的探讨复方盐酸阿替卡因在牙体牙髓病治疗中的应用效果。方法将2018年6月～2019年6月在我院口腔科治疗的100例牙体牙髓病患者按麻醉方法不同分为两组,对照组使用患牙唇侧根尖区黏膜下注射利多卡因2～4 m L麻醉,观察组使用患牙唇侧根尖区黏膜下复方盐酸阿替卡因0.6～0.8 mL麻醉,比较两组患者的麻醉有效率、麻醉起效时间和麻醉持续时间、麻醉前后血压与心率变化及不良反应情况。结果观察组麻醉总有效率为98.00%,明显高于对照组的80.00%(P0.05);观察组麻醉起效时间、感觉恢复时间明显短于对照组,麻醉持续时间明显长于对照组(P0.05);观察组麻醉后血压、心率平稳,而对照组舒张压下降、心率加快,差异有统计学意义(P0.05);观察组头晕、头痛、心动过速、恶心、呕吐等总不良反应发生率明显低于对照组(P0.05)。结论复方盐酸阿替卡因在牙体牙髓病治疗中效果显著,起效快,镇痛力强,感觉恢复快,且术中血流动力学平稳,不良反应发生率低,具有较高的应用价值。     

水陆地黄汤联合盐酸贝那普利对气阴两虚夹瘀型糖尿病肾病氧化应激及临床指标的影响

目的:观察水陆地黄汤对气阴两虚夹瘀型糖尿病肾病氧化应激及临床指标的影响。方法:60例气阴两虚夹瘀型糖尿病肾病患者随机分为对照组与联合组,每组30例,对照组给予盐酸贝那普利片10 mg,1次/d,联合组在对照组基础上加服水陆地黄汤,1剂/d。治疗12周后观察两组氧化应激指标:谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)及临床指标:空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、尿微量白蛋白(mALB)、24 h尿蛋白定量(24 hU-PQ)、肾小球滤过率(eGFR)的变化及临床症状的改善。结果:联合组治疗总有效率为90.0%,与对照组56.7%比较,差异有统计学意义(P<0.05);治疗后联合组MDA较治疗前均降低(P<0.05),SOD、GSH-Px均高于治疗前(P<0.05),与对照组比较,差异有统计学意义(P<0.05);联合组FPG、2 hPG、HbA1c、mALB、24 hU-PQ、eGFR较治疗前均降低(P<0.01)。结论:水陆地黄汤联合盐酸贝那普利可改善气阴两虚夹瘀型糖尿病肾病氧化应激状态,明显缓解临床症状,延缓病程进展。     

Sinomenine hydrochloride inhibits the progression of plasma cell mastitis by regulating IL-6/JAK2/STAT3 pathway

Plasma cell mastitis (PCM) is a special form of mastitis characterized by periductal inflammation and large-scale plasma cell infiltration. At present, the recurrence rate of PCM after excision is quite high, making PCM a major problem for mammary surgeons. However, no effective drug exists for the treatment of PCM. Numerous studies have demonstrated that Sinomenine hydrochloride (SH) has potent anti-inflammatory and immunoregulatory properties. However, the efficacy and the underlying mechanisms of SH in the treatment of PCM remain unclear. In the present study, we first investigated the therapeutic effects of SH in the PCM mouse model and clarified the possible mechanisms. We found that the levels of plasmocytes and lymphocytes infiltration were alleviated significantly in the 100 mg/kg SH group compared to the control group. In addition, few CD138+ plasma cells were found in the mammary glands of the 100 mg/kg SH group. The levels of Bcl-2 in the 100 mg/kg SH group were dramatically decreased compared with those in the saline group. Mechanistically, we demonstrated that SH inhibited the progression of PCM mainly through downregulating IL-6/JAK2/STAT3 levels. Collectively, our results suggested that SH could inhibit the progression of PCM by suppressing IL-6/JAK2/STAT3 cascades and ultimately achieve a therapeutic effect in PCM. This study provides theoretical support for the clinical application of SH in the treatment of PCM.